Due Diligence Guide · Fertility Clinic

Due Diligence Guide for Acquiring a Fertility Clinic

A structured checklist for buyers evaluating IVF practices — from physician retention risk and SART outcomes to laboratory accreditation and payer mix analysis.

Find Fertility Clinic Acquisition Targets

Acquiring a fertility clinic requires scrutiny well beyond standard healthcare M&A. Success rates are publicly reported, physician dependency is acute, and regulatory obligations span CLIA, SART, CDC, and state corporate practice of medicine laws. This guide walks buyers through three critical phases to protect deal value and avoid post-close surprises.

Fertility Clinic Due Diligence Phases

01

Phase 1: Clinical and Regulatory Review

Validate the clinic's licensure, accreditation standing, and published clinical outcomes before advancing toward LOI or exclusivity.

SART and CDC ART Outcome Reportscritical

Review last three years of SART-reported IVF success rates and CDC ART data. Confirm rates meet or exceed national averages and identify any adverse reporting history.

CLIA and State Laboratory Licensurecritical

Verify the IVF laboratory holds current CLIA certification and all state-required licenses. Confirm accreditations are transferable to the acquiring entity post-close.

Malpractice and Regulatory Citation Historycritical

Request five years of malpractice claims, patient complaints, and state health department citations. Unresolved claims or regulatory sanctions are serious red flags.

02

Phase 2: Physician and Workforce Assessment

Evaluate dependency on the founding reproductive endocrinologist and assess the strength of employment agreements and staff retention plans.

Physician Employment Agreements and Non-Competescritical

Review all RE employment contracts, compensation terms, non-compete radius and duration, and tail malpractice coverage obligations triggered at separation.

Single-Physician Dependency Riskcritical

Assess patient volume attributable to the founding physician. Quantify revenue at risk if departure occurs and evaluate associate RE bench strength and recruiting pipeline.

Key Staff and Embryologist Retentionimportant

Identify credentialed embryologists, clinical coordinators, and nurses critical to lab operations. Review compensation, tenure, and any flight risk indicators post-announcement.

03

Phase 3: Financial and Commercial Diligence

Analyze revenue quality, payer mix, capital requirements, and deal structure implications for post-close performance.

Payer Mix and Reimbursement Contractscritical

Break down revenue by self-pay IVF cycles, insurance mandates, and employer benefit contracts such as Progyny or WINFertility. Assess reimbursement rates and contract renewal terms.

IVF Laboratory Equipment Condition and CapEximportant

Inspect age and condition of incubators, cryostorage systems, and genetic testing equipment. Obtain third-party estimates for near-term capital replacement requirements.

Quality of Earnings Normalizationcritical

Engage a QoE provider to normalize founding physician compensation, personal expenses, and one-time items. Confirm true EBITDA supports the acquisition multiple being paid.

Fertility Clinic-Specific Due Diligence Items

  • Confirm embryo storage agreements and disposition consent protocols are fully documented and HIPAA-compliant for all cryopreserved specimens currently held.
  • Assess the clinic's legal entity structure for compliance with state corporate practice of medicine laws and validate the MSO or PSA structure proposed for the transaction.
  • Review employer fertility benefit platform contracts including Progyny and WINFertility for patient volume guarantees, exclusivity clauses, and post-acquisition transferability.
  • Evaluate exposure to state embryo personhood legislation or pending reproductive health regulations that could materially restrict ART service delivery post-close.
  • Audit donor egg and third-party reproduction contracts for legal compliance, donor anonymity obligations, and any outstanding litigation involving donor or surrogacy arrangements.

Frequently Asked Questions

Is SBA financing available for acquiring a fertility clinic?

No. Fertility clinic acquisitions are not SBA eligible due to their healthcare nature and typical deal structures involving MSOs, physician equity rollovers, and earnout provisions that conflict with SBA requirements.

What EBITDA multiple should I expect to pay for a fertility clinic?

Expect five to nine times EBITDA depending on SART performance, physician stability, lab accreditation, and payer mix quality. Clinics with multiple REs and above-average success rates command the higher end.

How do I structure an acquisition to comply with corporate practice of medicine laws?

Most deals use a Management Services Organization structure where the MSO owns non-clinical assets and the physician entity retains clinical operations, linked through a Professional Services Agreement compliant with state CPOM doctrine.

What happens if the founding physician leaves after I acquire the clinic?

Patient volume and referral relationships can collapse rapidly. Mitigate this through a multi-year employment agreement with non-compete provisions, earnout tied to retention, and recruitment of an associate RE before closing.

More Fertility Clinic Guides

Find Fertility Clinic businesses ready for acquisition

DealFlow OS surfaces targets with seller signals and motivation scores — so you know before you start diligence. Free to join.

Start finding deals — free

No credit card required